Atea Pharmaceuticals, Inc.

Listed Company

AVIRCIK 0001593899NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsMassachusettsFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-158.35M

Total Assets

$315.22M

Equity

$275.43M

Shares Out

79.67M

Op. Cash Flow

$-132.03M

Business

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel orally administered antiviral product candidates for serious viral diseases. It is developing a lead regimen combining bemnifosbuvir and ruzasvir for the treatment of chronic hepatitis C virus (HCV) infection and pursues discovery programs for respiratory and other single-stranded RNA viruses. Its business is organized around research and development, clinical development and regulatory activities, intellectual property and strategic licensing and collaboration. Atea conducts global clinical trials across North America and ex-North America regions and pursues commercialization through strategic partnerships and third-party manufacturing and distribution channels.

Summary from filing dated 2025-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	148	144	114	82	167
General and administrative	33	49	50	49	46
Total operating expenses	181	193	164	131	213
Loss from operations	−181	−193	−164	−131	138
Interest income and other, net	16	25	29	11	213,000
Loss before income taxes	−165	−167	−135	−119	139
Income tax benefit (expense)	6	−925,000	−1	4	−17
Net loss	−158	−168	−136	−116	121
Unrealized (loss) gain on available-for-sale investments	−59,000	26,000	891,000	−684,000	—
Comprehensive loss	−158	−168	−135	−117	121
Net loss per share - basic	−1.94	−2	−1.63	−1.39	1.46
Net loss per share - diluted	−1.94	−2	−1.63	−1.39	1.37
Weighted-average number of common shares - basic	81	84	83	83	83
Weighted-average number of common shares - diluted	81	84	83	83	88

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	96	65	144	188	764
Marketable securities	206	390	434	458	—
Prepaid expenses and other current assets	9	8	12	14	8
Total current assets	311	462	590	661	772
Property and equipment, net	457,000	873,000	1	2	23,000
Other assets	3	197,000	1	1	466,000
Operating lease right-of-use assets, net	634,000	1	2	2	161,000
Total assets	315	465	595	667	773
Accounts payable	13	4	4	3	5
Accrued expenses and other current liabilities	26	13	27	15	52
Current portion of operating lease liabilities	843,000	800,000	760,000	721,000	197,000
Total current liabilities	40	19	32	18	57
Operating lease liabilities	0	842,000	2	2	—
Income taxes payable	0	6	6	5	6
Total liabilities	40	26	40	26	63
Commitments and contingencies (see Note 7)	—	—	—	—	—
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and 2023	—	—	—	—	—
Common stock, $0.001 par value; 300,000,000 shares authorized; 78,126,796 and 84,463,059 shares issued and outstanding as of December 31, 2025 and 2024	78,000	84,000	83,000	83,000	83,000
Additional paid-in capital	798	803	751	701	654
Accumulated other comprehensive gain	174,000	233,000	207,000	−684,000	—
Accumulated deficit	−523	−364	−196	−60	56
Total stockholders equity	275	439	555	641	710
Total liabilities and stockholders equity	315	465	595	667	773

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−158	−168	−136	−116	121
Stock-based compensation expense	21	52	49	47	40
Depreciation and amortization expense	416,000	416,000	416,000	260,000	29,000
Accretion of premium and discounts on marketable securities	−5	−12	−15	−5	—
Income tax benefit	−6	0	—	—	—
Prepaid expenses and other current assets	−2	6	2	−6	−483,000
Other assets	−3	0	98,000	−1	−161,000
Accounts payable	8	206,000	2	−2	10
Accrued expenses and other liabilities	13	−13	13	−38	44
Operating lease liabilities	−190,000	−175,000	−161,000	765,000	—
Net cash used in operating activities	−132	−135	−85	−121	−87
Purchases of marketable securities	−282	−461	−562	−545	—
Sales and maturities of marketable securities	471	517	603	92	—
Net cash provided by investing activities	189	56	40	−455	−4,000
Proceeds from issuance of common stock under ESPP	201,000	267,000	257,000	140,000	—
Proceeds from issuance of common stock upon option exercise	58,000	0	—	230,000	1
Stock repurchase	−26	0	—	—	—
Cash paid for taxes in connection with RSU and PSU vesting	−485,000	0	—	—	—
Net cash (used in) provided by financing activities	−26	267,000	257,000	370,000	1
Net increase (decrease) in cash and cash equivalents	31	−79	−45	−576	−86

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro